Cardiovascular & Hematological Disorders-Drug Targets

(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Garry X. Shen  
University of Manitoba
Winnipeg, MB


Stem Cell Therapy in Chronic Ischemic Heart Dysfunction with and Without Viability

Author(s): Pedro L. Sanchez, Ricardo Sanz-Ruiz, M. Eugenia Fernandez-Santos, Adolfo Villa, Enrique Gutierrez, Lucia Fernandez, Sandra Vazquez, M. Jose Lorenzo, Francisco Fernandez-Aviles.


A growing number of clinical trials are evaluating the effects of stem cell therapy in patients with chronic ischemic heart dysfunction. As most of the clinical trials included a limited and different number of patients, various stem cell sources and several delivery approaches, results vary substantially between these studies. We analyse whether the assessment of myocardial viability may be important when evaluating effects of stem cell transplantation on parameters of left ventricular remodeling. Viability assessment could help to find the best type of stem cell and the best method of cell delivery to be used in chronic ischemic heart dysfunction.

Keywords: Stem cell, ischemic heart disease, viability, left ventricular function, coronary artery bypass graft surgery, CABG, single-photon emission computed tomography, SPECT, positron emission tomo- graphy, PET, magnetic resonce imaging, MRI, Echocardiography, left ventricle ejection fraction, LVEF, plasticity, Skeletal myoblasts, myocardial contractility, Adipose-derived stem cells, circulating progenitor cells, CPC, granulocyte colony, G-CSF, MAGIC Cell-3-DES, bone marrow mononuclear cells, BMMC, TOPCARE-CHD trial, NOGA electromechanical mapping, PROTECT-CAD trial

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2010
Page: [167 - 172]
Pages: 6
DOI: 10.2174/1871529X11006030167
Price: $58